Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

Area of Science:

• Oncology
• Immunotherapy
• Pulmonology

Background:

• The treatment landscape for driver-negative non-small-cell lung cancer (NSCLC) is rapidly evolving.
• Immune-checkpoint inhibitors targeting PD-1/PD-L1 are now a cornerstone of first-line therapy for NSCLC.
• Current treatment strategies include monotherapy, immunotherapy-exclusive regimens, and chemotherapy-immunotherapy combinations.

Purpose of the Study:

• To review the current treatment landscape for first-line immunotherapy in advanced-stage, driver-negative NSCLC.
• To provide an approach for selecting optimal immunotherapy regimens.
• To discuss the role of emerging biomarkers and novel therapeutic strategies.

Main Methods:

• Analysis of long-term efficacy and safety data from pivotal clinical trials.
• Consideration of histological subtype and PD-L1 expression for regimen selection.
• Evaluation of clinicopathological factors and patient preferences.

Main Results:

• Durable efficacy has been demonstrated with PD-1/PD-L1 inhibitors in a subset of NSCLC patients.
• Histological subtype and PD-L1 expression levels are critical for selecting first-line immunotherapy regimens.
• Optimal management requires careful consideration of complex decision-making factors due to limited head-to-head comparisons.

Conclusions:

• First-line immunotherapy selection for driver-negative NSCLC is complex and multifactorial.
• Histology and PD-L1 expression are paramount in guiding treatment decisions.
• Emerging biomarkers and therapies promise to further refine the treatment paradigm for advanced NSCLC.